Literature DB >> 11688574

Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.

M H Cessna1, H Zhou, S L Perkins, S R Tripp, L Layfield, C Daines, C M Coffin.   

Abstract

Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood, displays a variety of histologic patterns. Immunohistochemistry is used extensively to distinguish RMS from its mimics. Myogenin and MyoD1, myogenic transcriptional regulatory proteins expressed early in skeletal muscle differentiation, are considered sensitive and specific markers for RMS and are more specific than desmin and muscle-specific actin and more sensitive than myoglobin. Previous studies have focused on expression of myogenin and MyoD1 in small round cell tumors. This study assesses myogenin and MyoD1 in rhabdomyosarcoma subtypes and spindle cell tumors considered in the differential diagnosis of RMS. Formalin-fixed, paraffin-embedded archival tissue from 32 RMS, 107 non-RMS, and 11 benign skeletal muscle samples was stained for myogenin and MyoD1 with standard immunohistochemical techniques. Nuclear positivity was scored on a three-tiered scale. All RMSs expressed myogenin. Alveolar RMS (ARMS) showed strong nuclear staining, especially in tumor cells lining fibrous septae and perivascular regions. In cases with a subtle alveolar architecture on routinely stained sections, myogenin highlighted and enhanced visualization of the alveolar morphologic pattern. Embryonal RMSs (ERMSs) were more variable in myogenin staining pattern and intensity. No cases of nodular fasciitis, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, inflammatory myofibroblastic tumor, myofibrosarcoma, leiomyoma, leiomyosarcoma, or alveolar soft part sarcoma stained for myogenin. Focal nuclear reactivity was seen in desmoid (2 of 10), infantile myofibromatosis (2 of 10), synovial sarcoma (1 of 10), and infantile fibrosarcoma (2 of 10). Non-neoplastic skeletal muscle fiber nuclei stained positively for myogenin in both tumor-associated samples (25 of 40) and benign skeletal muscle samples (5 of 11). Although all RMSs were immunoreactive for MyoD1, cytoplasmic and nonspecific background staining and reactivity of nonmyoid tissues hindered its practical utility in paraffin-embedded samples in this study. Although myogenin is a highly sensitive and specific marker for RMS, it is rarely seen in other spindle cell soft tissue tumors. As previously reported, ARMS stained more strongly than ERMS. In contrast to previous studies, rare non-RMS (7 of 107) displayed focal nuclear reactivity, and entrapped atrophic or regenerative skeletal muscle fibers also stained positively. Although these are potential pitfalls in the interpretation of myogenin, careful attention to morphology and other features, to the relative paucity of myogenin-positive nuclei in non-RMS. and to the presence of entrapped muscle fibers should prevent incorrect interpretation. Because the extent of myogenin expression in RMS is much greater than in non-RMS, it is a very useful marker when interpreted in the context of other clinicopathologic data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11688574     DOI: 10.1097/00000478-200109000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  53 in total

1.  Immunohistochemical detection of myogenin and p21 in methylcholanthrene-induced mouse rhabdomyosarcomas.

Authors:  Makoto Inoue; Haiyan Wu
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

Review 2.  Primary pulmonary rhabdomyosarcoma in an adult: a case report and review of the literature.

Authors:  Gui-yi Ji; Hui Mao
Journal:  J Zhejiang Univ Sci B       Date:  2013-09       Impact factor: 3.066

3.  Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.

Authors:  L Krsková; M Mrhalová; D Sumerauer; R Kodet
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

4.  Orthopaedic case of the month: A 14-year-old boy with a medial thigh soft tissue mass.

Authors:  David A Ibrahim; Leo Mascarenhas; Jason P Tovar; Alexandre Arkader
Journal:  Clin Orthop Relat Res       Date:  2013-05       Impact factor: 4.176

Review 5.  Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers.

Authors:  Markku Miettinen
Journal:  Histopathology       Date:  2013-11-28       Impact factor: 5.087

6.  Misdiagnosed infantile rhabdomyofibrosarcoma: A case report.

Authors:  Tao Pan; Ken Chen; Run-Song Jiang; Zheng-Yan Zhao
Journal:  Oncol Lett       Date:  2016-08-17       Impact factor: 2.967

Review 7.  Alveolar soft-part sarcoma: a review and update.

Authors:  A L Folpe; A T Deyrup
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

8.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Authors:  Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.

Authors:  Xiaofan Lu; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Xiao Lin; Yue Wang; Qianyuan Zhang; Tao Lu; Fangrong Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.